CCP
HAE icon

Carmel Capital Partners’s Haemonetics HAE Stock Holding History

Carmel Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,104
Closed -$250K – 155
2024
Q3 		$250K Sell
3,104
-81
-3% -$6.54K 0.1% 147
2024
Q2 		$263K Buy
+3,185
New +$280K 0.11% 126
2023
Q4 		– Sell
-336
Closed -$30.1K – 374
2023
Q3 		$30.1K Buy
+336
New +$30K 0.01% 296

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Carmel Capital Partners's HAE Position: Q4 2024 in Review

Carmel Capital Partners sold out of Haemonetics (HAE) in Q4 2024, closing a stake of 3,104 shares — an estimated $250K sold.

Carmel Capital Partners first reported a position in HAE in Q3 2023 and held it in 3 quarters. The position peaked at $263K in Q2 2024. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

  • Carmel Capital Partners reported no remaining Haemonetics position as of Q4 2024 after selling out during the quarter.
  • Carmel Capital Partners sold 3,104 Haemonetics shares in Q4 2024, an estimated $250K.
  • Carmel Capital Partners first reported a position in Haemonetics in Q3 2023 and held it in 3 quarters.
  • Carmel Capital Partners's Haemonetics position peaked at $263K in Q2 2024.
  • 309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Carmel Capital Partners's 13F filing for Q4 2024, filed 6 Feb 2025.